지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2002.6
- 수록면
- 128 - 133 (6page)
이용수
초록· 키워드
오류제보하기
It has been postulated that dopamine(DA) is a key neurotransmitter in the pathogenesis of schizophrenia. The significance of plasma concentration of the major metabolite of DA, homovanillic acid(HVA), was investigated in this study. Sixteen patients with schizophrenia were enrolled after 2 week washout of neuroleptics. Plasma were taken before neuroleptic treatment, post-neuroleptic samplings were done at 2 week and 4 week point after neuroleptic treatment. Plasma HVA(pHVA) levels following nemonapride or olanzapine treatment were assayed by high pressure liquid chromatography with electrochemical detection.
The pHVA levels increased significantly after 2 week treatment with nemonapride, then the levels decreased after 4 week treatment. The pHVA levels increased significantly after 2 week treatment with olanzapine, then the levels continuously increased after 4 week treatment.
There was no significant difference in pHVA levels between nemonapride group and olanzapine group at starting point after neuroleptic washout, but pHVA levels of olanzapine group were significantly higher than those of nemonapride group at 2 week and 4 week point after treatment.
The chronic treatment with nemonapride and olanzapine induced different changes in the dopaminergic system. Olanzapine is an atypical neuroleptics and nemonapride is regarded as typical neuroleptics. This finding suggests that different mechanism might be related to the antipsychotic effect of atypical neuroletpics in contrast to classical neuroleptics. The contribution of other neurotransmitter systems, possibly serotonin, GABA, or glutamate, may explain this differential finding. In the near future we will try to delineate this finding in extended research.
The pHVA levels increased significantly after 2 week treatment with nemonapride, then the levels decreased after 4 week treatment. The pHVA levels increased significantly after 2 week treatment with olanzapine, then the levels continuously increased after 4 week treatment.
There was no significant difference in pHVA levels between nemonapride group and olanzapine group at starting point after neuroleptic washout, but pHVA levels of olanzapine group were significantly higher than those of nemonapride group at 2 week and 4 week point after treatment.
The chronic treatment with nemonapride and olanzapine induced different changes in the dopaminergic system. Olanzapine is an atypical neuroleptics and nemonapride is regarded as typical neuroleptics. This finding suggests that different mechanism might be related to the antipsychotic effect of atypical neuroletpics in contrast to classical neuroleptics. The contribution of other neurotransmitter systems, possibly serotonin, GABA, or glutamate, may explain this differential finding. In the near future we will try to delineate this finding in extended research.
목차
영어 초록
서론
연구 대상 및 방법
연구 결과
고찰
요약 및 결론
참고문헌
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
네모나프라이드의 유효성 및 추체외로 부작용 : Haloperidol 및 Risperidone과의 자연관찰적 개방형 비교연구
생물치료정신의학
2001 .12
-
정신분열증환자에서 Haloperidol 투여에 따른 임상효과와 혈장 Homovanillic Acid의 농도 및 혈장 5-Hydroxyindoleacetic Acid 농도와의 관계
생물정신의학
1995 .01
-
Olanzapine-induced Orthostatic Hypotensio
Clinical Psychopharmacology and Neuroscience
2015 .01
-
올란자핀의 체중증가 부작용 발생율 및 체중변화량
약학회지
2008 .01
-
Clozapine과 Risperidone에서 Olanzapine으로 교체 연구 : 12개월 추적연구
생물정신의학
2001 .01
-
정신분열병 또는 정신분열형장애를 가진 입원환자에서 Risperidone과 Olanzapine의 효과의 비교 : 6주간의 개방적 전향적 연구
생물치료정신의학
2003 .12
-
Olanzapine에 의해 당뇨병성 케톤산증으로 진행한 환자 1예
신경정신의학
2007 .01
-
Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation
The Korean Journal of Pain
2015 .01
-
G-protein β3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients
PSYCHIATRY INVESTIGATION
2009 .01
-
Olanzapine May Inhibit Colonic Motility Associated with the 5-HT Receptor and Myosin Light Chain Kinase
PSYCHIATRY INVESTIGATION
2016 .01
-
정신분열증환자에서 Nemonapride와 Haloperidol의 치료결과 및 내약성에 대한 비교분석
생물정신의학
1995 .01
-
2회의 임신 전 기간 동안 Olanzapine을 사용한 분열정동장애 환자 : 각각 생후 35개월과 14개월 나이 때까지의 추적관찰
생물치료정신의학
2008 .12
-
정신분열병 환자에서 Olanzapine이 인지기능에 미치는 영향
생물치료정신의학
2001 .06
-
Frequency and Outcome of Neuroleptic Rotation in the Management of Delirium in Patients with Advanced Cancer
Cancer Research and Treatment
2015 .01
-
Delirium Associated with Olanzapine Therapy in an Elderly Male with Bipolar Affective Disorder
PSYCHIATRY INVESTIGATION
2010 .01
-
Adjunctive Risperidone and Olanzapine in the Treatment of Patients with Bipolar I Disorder :A Retrospective Study
Clinical Psychopharmacology and Neuroscience
2005 .01
-
정신과 입원환자에서 Olanzapine의 처방경향에 대한 연구 : 한국과 미국의 일 대학병원에서 사용비교
생물치료정신의학
2001 .06
-
Olanzapine 복용 이후 당뇨병 케톤산증이 발생한 정신분열병 환자
신경정신의학
2005 .01
-
신장이식 후 Cyclosporine 사용 중 발생한 조증환자에 대한 Olanzapine 치험례
생물치료정신의학
2008 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2009-513-017218990